Shane Maltbie - 17 Sep 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Reporting relationship: Chief Financial Officer
Issuer ticker: HLVX
Reported as of: 17 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Sep 2025, 16:30:04 UTC
Prior SEC filing: 12 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Bavier, Attorney-in-Fact for Shane Maltbie

Key filing fact

Shane Maltbie filed Form 4 for HilleVax, Inc. (HLVX) on 17 Sep 2025.

Key facts

This page summarizes Shane Maltbie's Form 4 filing for HilleVax, Inc. (HLVX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Sep 2025, 16:30.

Change

Previous filing in this sequence was filed on 12 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001786301 Primary reporting owner

Maltbie Shane

Relationship: Chief Financial Officer
Address: C/O HILLEVAX, INC., 321 HARRISON AVE, SUITE 500, BOSTON
Signature: /s/ Paul Bavier, Attorney-in-Fact for Shane Maltbie
Signature date: 17 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLVX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -83,738
Change %: -100%
Price
Shares after: 0
Date: 17 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Shane Maltbie is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.